MPG.eBooks - Search Results

1

Golimumab (Simponi) IV : in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis

Published 2015

Canadian Agency for Drugs and Technologies in Health

Read Now

2

Golimumab (Simponi) IV : in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis

Published 2015

Canadian Agency for Drugs and Technologies in Health

Read Now

3

Galsulfase (Naglazyme)

Published 2016

Canadian Agency for Drugs and Technologies in Health

Subjects: “...N-Acetylgalactosamine-4-Sulfatase / therapeutic use...”

Read Now

4

Clinical review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild to moderate atopic dermatitis in patients 2 years of ag...

Published 2019

CADTH

Subjects: “...Phosphodiesterase 4 Inhibitors / adverse effects...”

Read Now

5

Pharmacoeconomic review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two y...

Published 2019

CADTH

Subjects: “...Phosphodiesterase 4 Inhibitors / therapeutic use...”

Read Now

6

Pharmacoeconomic review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two y...

Published 2019

CADTH

Subjects: “...Phosphodiesterase 4 Inhibitors / therapeutic use...”

Read Now

7

Elosulfase alfa (Vimizim)

Published 2015

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Mucopolysaccharidosis IV / drug therapy...”

Read Now

8

Clinical review report: Ustekinumab (Stelara/Stelara I.V.) Janssen Inc....

Published 2020

Canadian Agency for Drugs and Technologies in Health

“...Ustekinumab (Stelara/Stelara I.V.) Janssen Inc....”

Read Now

9

Pharmacoeconomic review report: Ustekinumab (Stelara/Stelara I.V.) Janssen Inc....

Published 2020

Canadian Agency for Drugs and Technologies in Health

Read Now

10

Patient group input submissions: Ivabradine (Lancora) for heart failure, NYHA class II to IV.

Published 2017

Canadian Agency for Drugs and Technologies in Health

“...Ivabradine (Lancora) for heart failure, NYHA class II to IV...”

Read Now

11

Patient group input submissions: Ivabradine (Lancora) for heart failure, NYHA class II to IV.

Published 2017

Canadian Agency for Drugs and Technologies in Health

“...Ivabradine (Lancora) for heart failure, NYHA class II to IV...”

Read Now

12

Combination use of insulin and incretins in type 2 diabetes

Published 2013

Canadian Agency for Drugs and Technologies in Health

Subjects: “...Dipeptidyl-Peptidase IV Inhibitors / therapeutic use...”

Read Now

13

OnabotulinumtoxinA for injection (Botox) for the prophylaxis of headaches in adults with chronic migraine ([equal to or greater than] 15 days per month with headache lasting 4 hours a day or longer)

Published 2015

Canadian Agency for Drugs and Technologies in Health

Read Now

14

OnabotulinumtoxinA for injection (Botox) for the prophylaxis of headaches in adults with chronic migraine ([equal to or greater than] 15 days per month with headache lasting 4 hours a day or longer)

Published 2015

Canadian Agency for Drugs and Technologies in Health

Read Now

15

CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children f...

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... for the treatment of severe vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence...”

Read Now

16

CADTH Canadian drug expert committee recommendation: Cyclosporine 0.1% (Verkazia -- Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children f...

Published 2019

Canadian Agency for Drugs and Technologies in Health

“... for the treatment of severe vernal keratoconjunctivitis (VKC) in children from four years of age through adolescence...”

Read Now

17

CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...

Published 2016

Canadian Agency for Drugs and Technologies in Health

“... with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)...”

Read Now

18

CADTH Canadian Drug Expert Committee final recommendation: Sapropterin -- resubmission (Kuvan -- BioMarin Pharmaceuticals Canada Inc.) : indication: to reduce blood phenylalanine l...

Published 2016

Canadian Agency for Drugs and Technologies in Health

“... with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU)...”

Read Now

19

CADTH Canadian drug expert committee recommendation: Ustekinumab (Stelara/Stelara I.V. -- Janssen...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“.... The recommended dosage for ustekinumab in the treatment of UC is as a single weight-based IV infusion...”

Read Now

20

Clinical review report: Cyclosporine (VERKAZIA) (Santen Canada Inc.) : indication : treatment of severe vernal keratoconjunctivitis in children from four years of age through adole...

Published 2020

Canadian Agency for Drugs and Technologies in Health

“... of the beneficial and harmful effects of 0.1% cyclosporine topical ophthalmic emulsion administered as one drop four...”

Narrow Search